Patents by Inventor David A. Sinclair

David A. Sinclair has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12624362
    Abstract: Provided herein are mutant reverse tetracycline transactivator (rtTA) proteins and engineered nucleic acids that encode a mutant rtTA that are useful in regulating gene expression, inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, treating a disease, or any combination thereof. Also provided herein are recombinant viruses comprising the engineered nucleic acids and methods of regulating cellular reprogramming, tissue repair, tissue regeneration, or any combination thereof by administering an engineered nucleic acid or recombinant virus comprising the same in a cell, tissue or subject comprising administering a mutant rtTA and an inducible nucleic acid encoding a transgene.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: May 12, 2026
    Inventors: David A. Sinclair, Yuancheng Lu, Noah Justin Davidsohn
  • Patent number: 12582698
    Abstract: Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g.
    Type: Grant
    Filed: February 21, 2024
    Date of Patent: March 24, 2026
    Assignee: President and Fellows of Harvard College
    Inventors: David A. Sinclair, Yuancheng Lu
  • Publication number: 20260068891
    Abstract: Provided herein are secretory compositions/cocktails derived from a novel, extremophilic fungal species cultured, isolated, and characterized herein. Said novel, extremophilic fungal species may be exploited to produce secretory compositions/cocktails which comprise a unique mixture of thermo-tolerant, stable enzymes capable of digesting cellular and genetic material in its surroundings under extreme temperatures. Such secretory compositions/cocktails may be useful as cleaning and sterilization solutions against biofilm, urine, yeast, bacterial, or viral contamination. Other uses include, but are not limited to, urea removal, fertilizer wastewaters, wastewater reclamation for life support systems in space, pH control, source of ammonia and carbon dioxide, starch digestion, biofuel production, as pharmaceuticals, and medical treatments such as wounds, skin disorders, or nail disorders.
    Type: Application
    Filed: November 12, 2025
    Publication date: March 12, 2026
    Inventors: David A. Sinclair, Kyle S. Landry
  • Publication number: 20260061028
    Abstract: Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g.
    Type: Application
    Filed: July 21, 2025
    Publication date: March 5, 2026
    Applicant: President and Fellows of Harvard College
    Inventors: David A. Sinclair, Yuancheng Lu
  • Publication number: 20260014229
    Abstract: Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g.
    Type: Application
    Filed: July 21, 2025
    Publication date: January 15, 2026
    Applicant: President and Fellows of Harvard College
    Inventors: David A. SINCLAIR, Yuancheng LU
  • Patent number: 12485135
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Grant
    Filed: November 21, 2023
    Date of Patent: December 2, 2025
    Assignee: Metro International Biotech, LLC
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczepankiewicz, Jonathan N. Kremsky
  • Publication number: 20250325628
    Abstract: Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g.
    Type: Application
    Filed: April 5, 2023
    Publication date: October 23, 2025
    Applicant: President and Fellows of Harvard College
    Inventors: David A. Sinclair, Xiao Tian
  • Patent number: 12414982
    Abstract: Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g.
    Type: Grant
    Filed: February 21, 2024
    Date of Patent: September 16, 2025
    Assignee: President and Fellows of Harvard College
    Inventors: David A. Sinclair, Yuancheng Lu
  • Patent number: 12409207
    Abstract: Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g.
    Type: Grant
    Filed: May 16, 2023
    Date of Patent: September 9, 2025
    Assignee: President and Fellows of Harvard College
    Inventors: David A. Sinclair, Yuancheng Lu
  • Patent number: 12274733
    Abstract: Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: April 15, 2025
    Assignee: President and Fellows of Harvard College
    Inventors: David A. Sinclair, Yuancheng Lu
  • Publication number: 20250114380
    Abstract: The invention provides methods and compositions for inhibiting CD38 activity, and methods of treating or preventing various disorders associated with CD38 activity.
    Type: Application
    Filed: June 10, 2024
    Publication date: April 10, 2025
    Applicants: President and Fellows of Harvard College, Mayo Foundation for Medical Education and Research
    Inventors: David A. Sinclair, Nathan L. Price, Eduardo N. Chini, Jon C. Clardy, Shugeng Cao
  • Patent number: 12252505
    Abstract: Provided herein are methods and compositions for preventing or treating aging, or an aging-related disorder, a disorder associated with inflammation, or for modulating an immune response in a subject in need thereof. In some embodiments, the methods comprise administering to the subject an effective amount of a compound of Formulas I-XIII.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: March 18, 2025
    Assignee: President and Fellows of Harvard College
    Inventors: David A. Sinclair, Conrad Rinaldi
  • Publication number: 20240350523
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Application
    Filed: November 21, 2023
    Publication date: October 24, 2024
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczepankiewicz, Jonathan N. Kremsky
  • Publication number: 20240316148
    Abstract: Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g.
    Type: Application
    Filed: February 21, 2024
    Publication date: September 26, 2024
    Applicant: President and Fellows of Harvard College
    Inventors: David A. Sinclair, Yuancheng Lu
  • Publication number: 20240261370
    Abstract: Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g.
    Type: Application
    Filed: February 21, 2024
    Publication date: August 8, 2024
    Applicant: President and Fellows of Harvard College
    Inventors: David A. Sinclair, Yuancheng Lu
  • Patent number: 11957703
    Abstract: The invention provides methods of modulating and regulating NHD protein-protein interactions through nicotinamide mononucleotide, analogs and derivatives thereof, such as NAD+. Such modulation may be useful in methods of treating and preventing cancer, aging, cell death, radiation damage, radiation exposure, among others, may improve DNA repair, cell proliferation, cell survival, among others, and may increase the life span of a cell or protect it against certain stresses, among others.
    Type: Grant
    Filed: May 5, 2022
    Date of Patent: April 16, 2024
    Assignees: President and Fellows of Harvard College, Metro International Biotech, LLC
    Inventors: David A. Sinclair, Jun Li, Karl D. Normington
  • Patent number: 11878027
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Grant
    Filed: July 26, 2022
    Date of Patent: January 23, 2024
    Assignee: Metro International Biotech, LLC
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczepankiewicz, Jonathan N. Kremsky
  • Publication number: 20230338468
    Abstract: Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g.
    Type: Application
    Filed: May 16, 2023
    Publication date: October 26, 2023
    Applicant: President and Fellows of Harvard College
    Inventors: David A. Sinclair, Yuancheng LU
  • Publication number: 20230293569
    Abstract: The invention provides methods of modulating and regulating NHD protein-protein interactions through nicotinamide mononucleotide, analogs and derivatives thereof, such as NAD+. Such modulation may be useful in methods of treating and preventing cancer, aging, cell death, radiation damage, radiation exposure, among others, may improve DNA repair, cell proliferation, cell survival, among others, and may increase the life span of a cell or protect it against certain stresses, among others.
    Type: Application
    Filed: May 5, 2022
    Publication date: September 21, 2023
    Inventors: David A. SINCLAIR, Jun Li, Karl D. Normington
  • Publication number: 20230220475
    Abstract: The present invention provides methods, compositions and kits for assembling an enzyme-deoxyribonucleic acid (DNA) complex for use in preparing a double stranded DNA molecule comprising one or more loci of interest for determining the methylation status of the one or more loci of interest therein.
    Type: Application
    Filed: June 11, 2021
    Publication date: July 13, 2023
    Inventors: Patrick Thomas Griffin, David A. Sinclair